Common variation in Cholesteryl Ester transfer protein: Relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio

Journal of Clinical Lipidology

Volumn 7, Issue 1, 2013, Pages 56-64

  Kappelle, Paul J W H ^a   Gansevoort, Ron T ^a   Hillege, Hans J ^a   Wolffenbuttel, Bruce H R ^a   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apolipoprotein A I; Apolipoprotein B; Cardiovascular risk; Cholesteryl Ester Transfer Protein gene; HDL cholesterol; Non HDL cholesterol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HEART DISEASE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 84872898064     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2012.05.003     Document Type: Article

References (39)

1. I. Tabas, K.J. Williams, and J. Borén Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 2007 1832 1844
2. I.M. Singh, M.H. Shishehbor, and B.J. Ansell High-density lipoproteins a therapeutic target JAMA 298 2007 786 798
3. Prospective Studies Collaboration S. Lewington, G. Whitlock, and R. Clarke Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 2007 1829 1839
4. The Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
5. P.J. Barter, C.M. Ballantyne, and R. Carmena Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel J Intern Med 259 2006 247 258
6. J.D. Brunzell, M. Davidson, and C.D. Furberg Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524
7. A.D. Sniderman, K. Williams, and J.H. Contois A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 435
8. A. Sniderman, K. Williams, and J. de Graaf Non-HDL C equals apolipoprotein B: except when it does not! Curr Opin Lipidol 21 2010 518 524
9. M.J. McQueen, S. Hawken, X. Wang INTERHEART study investigators Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study Lancet 372 2008 224 233
10. W.A. van der Steeg, and S.M. Boekholdt Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk Ann Intern Med 146 2007 640 648
11. P.J.W.H. Kappelle, R.T. Gansevoort, J.L. Hillege, B.H.R. Wolffenbuttel, R.P.F. Dullaart PREVEND study group Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein J Intern Med 269 2011 232 242
12. A.R. Tall Plasma cholesteryl ester transfer protein J Lipid Res 34 1993 1255 1274
13. S.E. Borggreve, R. De Vries, and R.P.F. Dullaart Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins Eur J Clin Invest 33 2003 1051 1069
14. P.J.W.H. Kappelle, A. van Tol, B.H.R. Wolffenbuttel, and R.P.F. Dullaart Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion Cardiovasc Ther 6 2011 e89 e99
15. L. Lagrost, H. Gandjini, A. Athias, V. Guyard-Dangremont, C. Lallemant, and P. Gambert Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects Arterioscler Thromb 6 1993 815 825
16. L. Lagrost, A. Athias, and B. Herbeth Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients J Biol Chem 271 1996 19058 19065
17. J.C. Hogue, B. Lamarche, and D. Gaudet Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia J Lipid Res 45 2004 1077 1083
18. A. Thompson, E. Di Angelantonio, and N. Sarwar Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk JAMA 299 2008 2777 2788
19. R.P.F. Dullaart, and W.J. Sluiter Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis Pharmacogenomics 9 2008 747 763
20. J.M. Ordovas, L.A. Cupples, and D. Corella Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study Arterioscler Thromb Vasc Biol 20 2000 1323 1329
21. K. Musunuru, M. Orho-Melander, and M.P. Caulfield Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk Arterioscler Thromb Vasc Biol 11 2009 1975 1980
22. B.M. Kaess, M. Tomaszewski, and P.S. Braund Large-scale candidate gene analysis of HDL particle features PLoS One 6 2011 e14529
23. H.J. Lambers Heerspink, A.H. Brantsma, D. de Zeeuw, S.J. Bakker, P.E. de Jong, R.T. Gansevoort PREVEND Study Group Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality Am J Epidemiol 168 2008 897 905
24. I. Simera, D. Moher, J. Hoey, Schultz, and D.G. Altman A catalogue of reporting guidelines for health research Eur J Clin Invest 40 2010 35 53
25. A.V. Chobanian, G.L. Bakris, and H.R. Black The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
26. S.J. Pinto-Sietsma, W.M. Janssen, H.L. Hillege, G. Navis, D. De Zeeuw, and P.E. De Jong Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population J Am Soc Nephrol 11 2000 1882 1888
27. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of diabetes mellitus Diabetes Care 20 1997 1183 1197
28. S.E. Borggreve, H.L. Hillege, B.H. Wolffenbuttel PREVEND Study Group The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides J Clin Endocrinol Metab 90 2005 4198 4204
29. S.E. Borggreve, H.L. Hillege, B.H.R. Wolffenbuttel PREVEND Study Group An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study J Clin Endocrinol Metab 91 2006 3382 3388
30. S.E. Borggreve, R. de Vries, and G.M. Dallinga-Thie The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the -629C - >A cholesteryl ester transfer protein promoter polymorphism: role of lecithin: cholesterol acyltransferase activity Biochim Biophys Acta 1781 2008 10 15
31. R.P.F. Dullaart, S.E. Borggreve, H.L. Hillege, and G.M. Dallinga-Thie The association of HDL cholesterol concentration with the -629C>A CETP promoter polymorphism is not fully explained by its relationship with plasma cholesteryl ester transfer Scand J Clin Lab Invest 68 2008 99 105
32. R.P.F. Dullaart, and W.J. Sluiter Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis Pharmacogenomics 9 2008 747 763
33. W.A. van der Steeg, I. Holme, and S.M. Boekholdt High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies J Am Coll Cardiol 51 2008 634 642
34. J.P. Corsetti, R.T. Gansevoort, C.E. Sparks, and R.P.F. Dullaart Inflammation reduces HDL protection against primary cardiac risk Eur J Clin Invest 40 2010 483 489
35. K. El Harchaoui, B.J. Arsenault, and R. Franssen High-density lipoprotein particle size and concentration and coronary risk Ann Intern Med 150 2009 84 93
36. S. Mora, J.D. Otvos, N. Rifai, R.S. Rosenson, J.E. Buring, and P.M. Ridker Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women Circulation 119 2009 931 939
37. P.J. Kappelle, F. Perton, H.L. Hillege, G.M. Dallinga-Thie, and R.P.F. Dullaart High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: A nested case-control study Atherosclerosis 217 2011 249 252
38. M. Vergeer, S.M. Boekholdt, and M.S. Sandhu Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility Circulation 122 2010 470 477
39. R.P.F. Dullaart, M. Vergeer, R. de Vries, P.J. Kappelle, and G.M. Dallinga-Thie Type 2 diabetes mellitus interacts with obesity and common variations in PLTP to affect plasma phospholipid transfer protein activity J Intern Med 271 2012 490 498